<?xml version="1.0" encoding="UTF-8"?>
<p id="p-13">Due to the self-renewal and multi-directional differentiation capability of mesenchymal stem cells, they can be differentiated to produce multifunctional cells. In damaged lung tissues, stem cells may be able to replenish bronchial epithelial and endothelial cells after the clearance of viral infection. They may also stabilize the pulmonary micro blood vessel and alveolar epithelial cell barriers. These effects could enhance the patient's immunity, alleviate pneumonia, and prevent secondary infections. As of February 14, 2020, more than 4 such projects have been approved for the treatment of COVID-19 in China, and another one has applied to the U.S. Food and Drug Administration (FDA) for emergency approval
 <sup>
  <xref rid="R5504" id="xref-bd40692c01ddd33ae843e6af10375033" ref-type="bibr">16</xref>
 </sup>.
</p>
